Shares Of Vical Dive After Clinical Trial Ineffective

by Benzinga Staff

September 22, 2010 2:00 PM | 12 seconds read | Make a Comment

Shares of Vical Inc

VICL

plunged more than 40% after a Phase III clinical trial shoed NV1FGF, the company's cardiovascular drug, to be immensely ineffective VICL is currently trading down off lows at $2.66, down 31%

Market News and Data brought to you by Benzinga APIs

Posted In: News Movers Biotechnology Health Care

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

-

-

-

-

-

-

-

25% Off Benzinga's Most Powerful Trading Tools

-

-

-

-

-

-

-

Shares Of Vical Dive After Clinical Trial Ineffective